Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Progenics Pharmaceuticals buy marge

Progenics Pharmaceuticals
Start price
€7.59
29.07.15 / 50%
Target price
€9.02
18.07.16
Performance (%)
-39.43%
End price
€4.60
18.07.16
Summary
This prediction ended on 18.07.16 with a price of €4.60. The BUY prediction by marge for Progenics Pharmaceuticals performed very badly with a performance of -39.43%. marge has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Progenics Pharmaceuticals - - - -
iShares Core DAX® -3,99 % -2,81 % 4,16 % 51,38 %
iShares Nasdaq 100 0,35 % -0,75 % 9,47 % 85,93 %
iShares Nikkei 225® -3,85 % 4,23 % 28,36 % 56,86 %
iShares S&P 500 0,30 % 0,38 % 6,14 % 59,57 %

Comments by marge for this prediction

In the thread Progenics Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) -39.43%
Target price 9.020
Change
Ends at 18.07.16

Mit vielversprechenden Onkology-Produkten in der Pipeline.

  • Progenics Pharmaceuticals (NASDAQ:PGNX) jumps 22% premarket on increased volume in response to its announcement that the FDA has granted Breakthrough Therapy status to Azedra for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma (tumor of the adrenal gland) and paraganglioma. Phase 2b-stage Azedra also has Orphan Drug and Fast Track designations.
  • Azedra (Ultratrace iobenguane I 131) is a highly specific activity form of the radiotherapeutic iobenquane I 131.
  • BTD status provides for more intensive guidance from the FDA, the involvement of more senior agency personnel and a rolling review of the New Drug Application (NDA). Orphan Drug status provides for a seven-year period of market exclusivity for the indication, if approved

    • http://seekingalpha.com/article/3254715-revisiting-the-investment-case-on-progenics-pharmaceuticals

    marge 
    0
    Report Share
    29.07.15
    Prediction Buy
    Perf. (%) -39.43%
    Target price 9.020
    Change
    Ends at 18.07.16

    (Laufzeit überschritten)

    marge 
    0
    Report Share
    18.07.16

    Stopped prediction by marge for Progenics Pharmaceuticals

    buy
    Progenics Pharmaceuticals

    Start price
    Target price
    Perf. (%)
    €6.50
    12.10.17
    €12.18
    25.12.18
    -49.51%
    25.12.18

    marge 
    14.08.19 50%
    buy
    Progenics Pharmaceuticals

    Start price
    Target price
    Perf. (%)
    €7.55
    20.07.15
    €9.02
    28.07.15
    26.45%
    28.07.15

    marge 
    14.08.19 50%